Cyclacel Pharmaceuticals Files 8-K on Asset Deal & Charter Changes
Ticker: BGMSP · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1130166
Sentiment: neutral
Topics: acquisition, corporate-action, filing
TL;DR
Cyclacel 8-K: Asset deal done, rights changed, bylaws amended. Big moves happening.
AI Summary
On September 12, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report indicating a completion of an acquisition or disposition of assets. The filing also noted material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. The company, formerly known as XCYTE THERAPIES INC, is incorporated in Delaware and has its principal business address in Berkeley Heights, NJ.
Why It Matters
This filing signals significant corporate actions, including asset transactions and potential changes to shareholder rights, which could impact the company's strategic direction and investor value.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate events like acquisitions/dispositions and modifications to security holder rights, which inherently carry medium risk due to potential impacts on the company's structure and value.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- September 12, 2025 (date) — Date of earliest event reported
- DE (state) — State of incorporation
- NJ (state) — State of business address
FAQ
What specific assets were acquired or disposed of by Cyclacel Pharmaceuticals, Inc. on or around September 12, 2025?
The filing indicates the 'Completion of Acquisition or Disposition of Assets' as an item of information, but the specific details of the assets are not provided in this excerpt.
How were the rights of Cyclacel Pharmaceuticals, Inc. security holders materially modified?
The filing lists 'Material Modifications to Rights of Security Holders' as an item of information, but the specific nature of these modifications is not detailed in this excerpt.
What amendments were made to Cyclacel Pharmaceuticals, Inc.'s articles of incorporation or bylaws?
The filing mentions 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item of information, but the specific amendments are not elaborated upon in this excerpt.
What is the significance of the 'Regulation FD Disclosure' mentioned in the filing?
The inclusion of 'Regulation FD Disclosure' suggests that the company is making public disclosures to ensure broad dissemination of material non-public information, as required by the regulation.
When did Cyclacel Pharmaceuticals, Inc. change its name from XCYTE THERAPIES INC?
The filing states that the date of the name change from XCYTE THERAPIES INC to Cyclacel Pharmaceuticals, Inc. was December 18, 2000.
Filing Stats: 1,570 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2025-09-12 06:07:02
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BGMS The Nasdaq Capital M
- $0 — 9,158 shares of common stock, par value $0.001, of the Company. Following the clos
Filing Documents
- form8-k.htm (8-K) — 59KB
- ex3-1.htm (EX-3.1) — 2KB
- ex10-1.htm (EX-10.1) — 118KB
- ex99-1.htm (EX-99.1) — 27KB
- ex99-2.htm (EX-99.2) — 31KB
- ex99-3.htm (EX-99.3) — 96KB
- form8-k_001.jpg (GRAPHIC) — 216KB
- ex3-1_001.jpg (GRAPHIC) — 541KB
- ex3-1_002.jpg (GRAPHIC) — 877KB
- ex10-1_001.jpg (GRAPHIC) — 5KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-013123.txt ( ) — 3086KB
- bgms-20250912.xsd (EX-101.SCH) — 4KB
- bgms-20250912_def.xml (EX-101.DEF) — 26KB
- bgms-20250912_lab.xml (EX-101.LAB) — 36KB
- bgms-20250912_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 12, 2025 Bio Green Med Solution, Inc. By: /s/ Datuk Dr. Doris Wong Sing Ee Name: Datuk Dr. Doris Wong Sing Ee Title: Chief Executive Officer and Executive Director 4